0001640455-18-000007.txt : 20180129
0001640455-18-000007.hdr.sgml : 20180129
20180129202632
ACCESSION NUMBER: 0001640455-18-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180126
FILED AS OF DATE: 20180129
DATE AS OF CHANGE: 20180129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duncan Barbara Gayle
CENTRAL INDEX KEY: 0001353128
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 18557290
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 18 DESBROSSES STREET
CITY: NEW YORK
STATE: NY
ZIP: 10013
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_151727557738985.xml
FORM 4
X0306
4
2018-01-26
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001353128
Duncan Barbara Gayle
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2018-01-26
4
M
0
4000
4.21
A
4000
D
Common Stock
2018-01-26
4
S
0
4000
25
D
0
D
Stock Option (Right to Buy)
4.21
2018-01-26
4
M
0
4000
4.21
D
2026-05-09
Common Stock
4000.0
46271
D
The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trade.
The Stock Option, representing the right to purchase a total of 50,271 shares of common stock, vests in 16 equal quarterly installments following May 10, 2016.
/s/ Anna L. Barry, Attorney-in-Fact
2018-01-29